ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

Core Insights - ORIC Pharmaceuticals is set to initiate a Phase 1b combination trial of ORIC-114 and subcutaneous amivantamab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations in Q1 2025, with initial data expected in mid-2026 [1][3] Company Overview - ORIC Pharmaceuticals is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance [1][6] - The company is dedicated to improving patients' lives by overcoming resistance in cancer, with product candidates including ORIC-114 and ORIC-944 [6] Product Details - ORIC-114 is a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor that targets EGFR exon 20, HER2 exon 20, and EGFR atypical mutations, showing promise for systemic and CNS antitumor activity [5][6] - The company has selected two provisional recommended Phase 2 doses (RP2D) for ORIC-114 at 80 mg and 120 mg QD, which are being evaluated in dose expansion cohorts [4] Trial Information - Under the supply agreement with Johnson & Johnson, ORIC will conduct and sponsor the trial while Johnson & Johnson will provide SC amivantamab [2] - The primary objectives of the trial include determining the RP2D for the combination and assessing efficacy and safety [3]